Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
2024 · The Lancet · 76 citations
https://doi.org/10.1016/s0140-6736(24)01762-8